Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537628 · ClinicalTrials.gov registry record
Biomarkers in Acute Heart Failure
A clinical trial, sponsored by Brahms.
- Completed
- Registry status
- 1,641
- Enrollment target
NCT00537628 is a clinical trial that has completed, run by Brahms. The registered enrollment target is 1,641 participants.
The verdict
NCT00537628 has completed, sponsored by Brahms.
- COMPLETED
- Registry status
- 1,641 participants
- Enrollment target
Study Summary
Primary Objectives 1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart failure (HF) patients and adds incremental value in predicting outcomes for patients presenting to the Emergency Department (ED) with shortness of breath. 2. Mid Region pro A-Type Natriuretic Peptide (MR-proANP) is non-inferior to BNP for the diagnosis of HF in patients presenting to the ED with shortness of breath.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,641 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00537628
The ClinicalTrials.gov registry entry for NCT00537628 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,641 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brahms, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00537628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00537628 about?
NCT00537628 is a clinical study titled "Biomarkers in Acute Heart Failure". Primary Objectives 1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart failure (HF) patients and adds incremental value in predicting outcomes for patients presenting to the Emergency Department (ED) with shortness of breath. 2. Mid Region pro A-Type Natriuret...
What is the current status of trial NCT00537628?
This trial is currently completed. The enrollment target is 1,641 participants. The study started on 2007-03. Estimated completion is 2008-06.
Who is sponsoring clinical trial NCT00537628?
This trial is sponsored by Brahms, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.